These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26692431)

  • 41. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined pharmacotherapy for TS and OCD.
    Hawkridge S; Stein DJ; Bouwer C
    J Am Acad Child Adolesc Psychiatry; 1996 Jun; 35(6):703-4. PubMed ID: 8682749
    [No Abstract]   [Full Text] [Related]  

  • 45. Evidence-based pharmacotherapy of obsessive-compulsive disorder.
    Fineberg NA; Gale TM
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):107-29. PubMed ID: 15450126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second-generation antipsychotics for obsessive compulsive disorder.
    Komossa K; Depping AM; Meyer M; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008141. PubMed ID: 21154394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder.
    Walsh KH; McDougle CJ
    Expert Opin Pharmacother; 2004 Oct; 5(10):2059-67. PubMed ID: 15461541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A meta-analysis of dropout rates from exposure with response prevention and pharmacological treatment for youth with obsessive compulsive disorder.
    Johnco C; McGuire JF; Roper T; Storch EA
    Depress Anxiety; 2020 May; 37(5):407-417. PubMed ID: 31778595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Female hormones affect symptom severity in obsessive-compulsive disorder.
    Vulink NC; Denys D; Bus L; Westenberg HG
    Int Clin Psychopharmacol; 2006 May; 21(3):171-5. PubMed ID: 16528139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.
    Poyurovsky M; Weizman A; Weizman R
    CNS Drugs; 2004; 18(14):989-1010. PubMed ID: 15584769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacotherapies in the management of obsessive-compulsive disorder.
    Blier P; Habib R; Flament MF
    Can J Psychiatry; 2006 Jun; 51(7):417-30. PubMed ID: 16838823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacotherapy for obsessive-compulsive disorder.
    Greist JH; Jefferson JW
    Br J Psychiatry Suppl; 1998; (35):64-70. PubMed ID: 9829028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of antipsychotics in the treatment of obsessive compulsive disorder.
    Fineberg NA; Gale TM; Sivakumaran T
    J Psychopharmacol; 2006 Jan; 20(1):97-103. PubMed ID: 16204331
    [No Abstract]   [Full Text] [Related]  

  • 58. Metabolic and toxicological considerations for obsessive-compulsive disorder drug therapy.
    Sayyah M; Majzoob S; Sayyah M
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):657-73. PubMed ID: 23521155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Obsessive-compulsive disorder: Under-recognized and responsive to treatment.
    Craner JR; Skillings JL; Barnes CR
    J Fam Pract; 2017 Aug; 66(8):503-506. PubMed ID: 28783772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series.
    Miodownik C; Bergman J; Lerner PP; Kreinin A; Lerner V
    Clin Neuropharmacol; 2015; 38(1):26-9. PubMed ID: 25580923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.